Fate Therapeutics (FATE) News Today $0.69 -0.08 (-10.39%) As of 03:59 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)April 2 at 4:01 PM | globenewswire.comFY2025 EPS Forecast for Fate Therapeutics Boosted by AnalystFate Therapeutics, Inc. (NASDAQ:FATE - Free Report) - Analysts at Cantor Fitzgerald boosted their FY2025 EPS estimates for Fate Therapeutics in a note issued to investors on Tuesday, March 18th. Cantor Fitzgerald analyst L. Watsek now anticipates that the biopharmaceutical company will post earniMarch 21, 2025 | marketbeat.comFate Therapeutics’ SWOT analysis: promising pipeline drives stock outlookMarch 14, 2025 | investing.comFate Therapeutics, Inc. (NASDAQ:FATE) Receives Average Recommendation of "Hold" from AnalystsShares of Fate Therapeutics, Inc. (NASDAQ:FATE - Get Free Report) have earned an average recommendation of "Hold" from the nine ratings firms that are covering the stock, MarketBeat Ratings reports. Seven equities research analysts have rated the stock with a hold rating and two have issued a buyMarch 13, 2025 | marketbeat.comFate Therapeutics (NASDAQ:FATE) Rating Lowered to "Sell" at StockNews.comStockNews.com downgraded shares of Fate Therapeutics from a "hold" rating to a "sell" rating in a report on Tuesday.March 11, 2025 | marketbeat.comBank of America Securities Keeps Their Hold Rating on Fate Therapeutics (FATE)March 10, 2025 | markets.businessinsider.comFate Therapeutics price target lowered to $2.50 from $3 at BofAMarch 10, 2025 | markets.businessinsider.comQ1 EPS Estimates for Fate Therapeutics Boosted by WedbushFate Therapeutics, Inc. (NASDAQ:FATE - Free Report) - Stock analysts at Wedbush raised their Q1 2025 EPS estimates for Fate Therapeutics in a research report issued to clients and investors on Wednesday, March 5th. Wedbush analyst D. Nierengarten now expects that the biopharmaceutical company wilMarch 10, 2025 | marketbeat.comFate Therapeutics, Inc. (NASDAQ:FATE) Just Reported, And Analysts Assigned A US$6.00 Price TargetMarch 8, 2025 | finance.yahoo.comFate Therapeutics, Inc Q4 Loss Misses EstimatesMarch 8, 2025 | nasdaq.comFate Therapeutics (NASDAQ:FATE) Price Target Lowered to $3.00 at Stifel NicolausStifel Nicolaus lowered their price objective on Fate Therapeutics from $5.00 to $3.00 and set a "hold" rating for the company in a research report on Thursday.March 7, 2025 | marketbeat.comFate Therapeutics (NASDAQ:FATE) Given New $4.00 Price Target at Wells Fargo & CompanyWells Fargo & Company lowered their target price on shares of Fate Therapeutics from $5.00 to $4.00 and set an "equal weight" rating on the stock in a report on Thursday.March 7, 2025 | marketbeat.comFate Therapeutics (NASDAQ:FATE) Earns "Neutral" Rating from WedbushWedbush reissued a "neutral" rating and issued a $5.00 price target on shares of Fate Therapeutics in a report on Thursday.March 7, 2025 | marketbeat.comNeedham & Company LLC Reiterates "Hold" Rating for Fate Therapeutics (NASDAQ:FATE)Needham & Company LLC reissued a "hold" rating on shares of Fate Therapeutics in a research note on Thursday.March 7, 2025 | marketbeat.comWedbush Remains a Hold on Fate Therapeutics (FATE)March 7, 2025 | markets.businessinsider.comFate Therapeutics (NASDAQ:FATE) Releases Earnings Results, Beats Expectations By $0.13 EPSFate Therapeutics (NASDAQ:FATE - Get Free Report) posted its earnings results on Wednesday. The biopharmaceutical company reported ($0.31) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.13. Fate Therapeutics had a negative net margin of 1,325.43% and a negative return on equity of 45.88%.March 6, 2025 | marketbeat.comFate Therapeutics (NASDAQ:FATE) Issues Quarterly Earnings ResultsFate Therapeutics (NASDAQ:FATE - Get Free Report) posted its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($0.31) EPS for the quarter, beating analysts' consensus estimates of ($0.44) by $0.13. Fate Therapeutics had a negative net margin of 1,325.43% and a negative return on equity of 45.88%.March 6, 2025 | marketbeat.comStifel Nicolaus Sticks to Their Hold Rating for Fate Therapeutics (FATE)March 6, 2025 | markets.businessinsider.comFate Therapeutics price target lowered to $3 from $5 at StifelMarch 6, 2025 | markets.businessinsider.comFate Therapeutics reports Q4 EPS (44c), consensus (42c)March 6, 2025 | markets.businessinsider.comFate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business UpdatesMarch 5, 2025 | globenewswire.comStockNews.com Upgrades Fate Therapeutics (NASDAQ:FATE) to HoldStockNews.com raised Fate Therapeutics from a "sell" rating to a "hold" rating in a research note on Monday.March 4, 2025 | marketbeat.comFate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)March 4, 2025 | globenewswire.comFate Therapeutics (FATE) Projected to Post Earnings on MondayFate Therapeutics (NASDAQ:FATE) will be releasing earnings before the market opens on Monday, February 24, Financial Modeling Prep reports.February 22, 2025 | marketbeat.comFate Therapeutics (FATE) Projected to Post Quarterly Earnings on MondayFate Therapeutics (NASDAQ:FATE) will be releasing earnings before the market opens on Monday, February 24, Financial Modeling Prep reports.February 17, 2025 | marketbeat.comFY2024 Earnings Forecast for FATE Issued By Leerink PartnrsFate Therapeutics, Inc. (NASDAQ:FATE - Free Report) - Leerink Partnrs issued their FY2024 EPS estimates for Fate Therapeutics in a report released on Thursday, February 13th. Leerink Partnrs analyst D. Graybosch anticipates that the biopharmaceutical company will post earnings per share of ($1.62February 17, 2025 | marketbeat.comFate Therapeutics, Inc. (NASDAQ:FATE) Receives Consensus Rating of "Hold" from AnalystsFate Therapeutics, Inc. (NASDAQ:FATE - Get Free Report) has earned an average recommendation of "Hold" from the ten research firms that are presently covering the firm, MarketBeat reports. Seven research analysts have rated the stock with a hold rating and three have assigned a buy rating to theFebruary 16, 2025 | marketbeat.comResearch Analysts Offer Predictions for FATE Q1 EarningsFate Therapeutics, Inc. (NASDAQ:FATE - Free Report) - Investment analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for Fate Therapeutics in a research note issued on Thursday, February 13th. Leerink Partnrs analyst D. Graybosch anticipates that the biopharmaceutical coFebruary 15, 2025 | marketbeat.comFate Therapeutics to Present at Upcoming Investor ConferencesFebruary 14, 2025 | globenewswire.comAnalysts Conflicted on These Healthcare Names: Sanofi (OtherSNYNF) and Fate Therapeutics (FATE)February 14, 2025 | markets.businessinsider.comSpringworks Therapeutics (SWTX) Gets a Buy from BarclaysFebruary 11, 2025 | markets.businessinsider.comMersana Therapeutics (MRSN) Receives a Buy from TD CowenFebruary 10, 2025 | markets.businessinsider.comProtagonist Therapeutics (PTGX) Gets a Buy from TD CowenFebruary 8, 2025 | markets.businessinsider.comWe're Keeping An Eye On Fate Therapeutics' (NASDAQ:FATE) Cash Burn RateFebruary 5, 2025 | finance.yahoo.comFate Therapeutics Has Promising Off-The-Shelf Cell Therapies While Looking CheapFebruary 4, 2025 | seekingalpha.comFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)February 4, 2025 | globenewswire.comFate Therapeutics' SWOT analysis: stock poised for catalysts amid clinical progressJanuary 30, 2025 | msn.comNatural killer cells, a rising alternative to CAR-T cell therapyJanuary 27, 2025 | finance.yahoo.comFate Therapeutics, Inc. (NASDAQ:FATE) Shares Sold by Assenagon Asset Management S.A.Assenagon Asset Management S.A. cut its stake in shares of Fate Therapeutics, Inc. (NASDAQ:FATE - Free Report) by 84.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 372,507 shares of the biopharmaceutJanuary 25, 2025 | marketbeat.comEquities Analysts Offer Predictions for FATE FY2025 EarningsFate Therapeutics, Inc. (NASDAQ:FATE - Free Report) - Research analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Fate Therapeutics in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst L. Watsek forecasts that the biopharmaceutical company will postJanuary 22, 2025 | marketbeat.comFate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Recommendation of "Hold" by BrokeragesFate Therapeutics, Inc. (NASDAQ:FATE - Get Free Report) has received an average recommendation of "Hold" from the ten ratings firms that are currently covering the company, Marketbeat reports. Seven equities research analysts have rated the stock with a hold rating and three have given a buy ratingJanuary 22, 2025 | marketbeat.comFate Therapeutics, Inc. (NASDAQ:FATE) Short Interest Down 8.1% in DecemberFate Therapeutics, Inc. (NASDAQ:FATE - Get Free Report) saw a large decrease in short interest during the month of December. As of December 31st, there was short interest totalling 11,200,000 shares, a decrease of 8.1% from the December 15th total of 12,190,000 shares. Based on an average daily volume of 2,950,000 shares, the short-interest ratio is presently 3.8 days.January 18, 2025 | marketbeat.comJPMorgan Chase & Co. Has $6.43 Million Stake in Fate Therapeutics, Inc. (NASDAQ:FATE)JPMorgan Chase & Co. raised its stake in Fate Therapeutics, Inc. (NASDAQ:FATE - Free Report) by 18.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,837,304 shares of the biopharmaceutical company's stock after buying an aJanuary 16, 2025 | marketbeat.comClinical trial: Off-the-shelf immunotherapy shows promise for B-cell lymphomaJanuary 14, 2025 | msn.comBarclays Issues a Buy Rating on Fate Therapeutics (FATE)January 14, 2025 | markets.businessinsider.comFate Therapeutics, Inc. (NASDAQ:FATE) CEO Bahram Valamehr Sells 8,705 SharesJanuary 14, 2025 | insidertrades.comCAR Natural Killer Cell Therapy Shows Promise in B-Cell LymphomasJanuary 13, 2025 | msn.comFate Therapeutics, Inc. (NASDAQ:FATE) CEO Sells $13,405.70 in StockFate Therapeutics, Inc. (NASDAQ:FATE - Get Free Report) CEO Bahram Valamehr sold 8,705 shares of the business's stock in a transaction that occurred on Friday, January 10th. The shares were sold at an average price of $1.54, for a total transaction of $13,405.70. Following the completion of the sale, the chief executive officer now owns 349,364 shares of the company's stock, valued at approximately $538,020.56. The trade was a 2.43 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.January 13, 2025 | marketbeat.comFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)January 3, 2025 | globenewswire.comInsider Buying: Fate Therapeutics, Inc. (NASDAQ:FATE) Director Purchases 397,964 Shares of StockDecember 27, 2024 | insidertrades.com Remove Ads Get Fate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FATE and its competitors with MarketBeat's FREE daily newsletter. Email Address FATE Media Mentions By Week FATE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. FATE News Sentiment▼0.000.57▲Average Medical News Sentiment FATE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. FATE Articles This Week▼14▲FATE Articles Average Week Remove Ads Get Fate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FATE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Stoke Therapeutics News REGENXBIO News Mereo BioPharma Group News Eton Pharmaceuticals News Cartesian Therapeutics News Entrada Therapeutics News Heron Therapeutics News Ginkgo Bioworks News Tectonic Therapeutic News Upstream Bio News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:FATE) was last updated on 4/3/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredNew “Trump” currency proposed in DCAfter a massive run-up – tech stocks are crashing. And as you’d suspect, the rich and powerful got out firs...Paradigm Press | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy FATE Stock Free FATE Stock Alerts